Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects.
about
A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue SarcomasPhenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model.The expression of sphingosine kinase-1 in head and neck carcinomaPharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2Sphingosine kinase 1 in cancer.Cancer treatment strategies targeting sphingolipid metabolism.Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancerInhibition of tumor angiogenesis by TTF1 from extract of herbal medicine.Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo.Targeting sphingosine-1-phosphate for cancer therapyA selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cellsTargeting SphK1 as a new strategy against cancer.Anti-tumor activity of phenoxodiol: from bench to clinic.The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro.Cytotoxic effects of the novel isoflavone, phenoxodiol, on prostate cancer cell lines.Genistein inhibits the development of atherosclerosis via inhibiting NF-kappaB and VCAM-1 expression in LDLR knockout mice.
P2860
Q26782842-AC16B8D6-F330-43F7-BBCB-B1A48F9F196CQ33292921-F7B9130A-7448-42C5-9DDB-0BC099772374Q33626361-1C9A3206-7498-45EB-BABF-FCB70E9EC9A4Q33755206-A991E3EE-D9FB-4827-BC51-3CBCF8D58C5DQ33853998-A5BDF800-FC20-4EF5-82DA-692EC05158E7Q34790629-683A7501-E06C-48CB-B035-9B2CFB3D0105Q34975827-ABEC8CA5-FC93-4015-BAFB-1EBE50042DD0Q35606919-EFCF0980-6785-49B5-9152-90E002E995FDQ35893432-D7EC46F6-AE41-4550-9676-FD39F184E539Q36615911-307C7CBE-88DE-4A7C-AE4C-3E007A304E48Q36835151-31F25066-F25B-4B0D-A305-1BF2F597E9A9Q37123431-BA9F359C-A768-4A64-8A72-65563A01D0E1Q37172893-10F7840A-9999-49EF-AA6A-92D6288338A0Q37236411-FB19ECEC-0C8D-457B-B440-F5DA0B8A83E5Q37246738-3C330F2E-4B3E-483A-BA36-6F6883238046Q38915115-FB89F715-9F6B-4033-B702-3EE9C46CC544Q39348586-CD259429-C5CC-45A8-B82C-456F7A16D50AQ39392134-F3FDA6BB-99D9-4BEB-B28F-17904A5A9C18Q46244538-5B062803-43F7-4E3D-BD25-1CD3D800D83B
P2860
Phenoxodiol, an experimental anticancer drug, shows potent antiangiogenic properties in addition to its antitumour effects.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@en
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@nl
type
label
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@en
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@nl
prefLabel
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@en
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@nl
P2093
P356
P1476
Phenoxodiol, an experimental a ...... ion to its antitumour effects.
@en
P2093
Christopher J Drogemuller
Christopher N Hahn
David Brown
Jennifer R Gamble
Jenny J Drew
Mathew A Vadas
P304
P356
10.1002/IJC.21682
P577
2006-05-01T00:00:00Z